Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Zelira Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $52.37 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.19 billion
Earnings per share -0.008
Dividend per share N/A
Year To Date Return -52.17%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

Zelira Therapeutics Ltd (ASX: ZLD)
Latest News

ZLD ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Zelira Therapeutics Ltd

Zelira Therapeutics Ltd (ASX: ZLD) is a leading global therapeutic medicinal cannabis company with access to the world’s fastest growing cannabis markets. Formerly Zelda Therapeutics, Zelira owns a portfolio of proprietary products and a pipeline of candidates undergoing clinical development.

The company focus is on developing branded cannabis products for the treatment of a variety of medical conditions, including insomnia, autism and opioid reduction. Zelira has launched two proprietary formulations under the HOPE brand for autism in multiple US-states with plans to expand into global markets in 2020. 

ZLD Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 Aug 2021 $0.04 $0.00 0.00% 356,915 $0.05 $0.05 $0.04
30 Jul 2021 $0.04 $0.00 0.00% 929,934 $0.05 $0.05 $0.04
29 Jul 2021 $0.05 $0.00 0.00% 1,066,760 $0.05 $0.05 $0.05
28 Jul 2021 $0.05 $0.00 0.00% 674,049 $0.05 $0.05 $0.05
27 Jul 2021 $0.05 $0.00 0.00% 397,583 $0.05 $0.05 $0.05
26 Jul 2021 $0.05 $0.00 0.00% 1,037,577 $0.05 $0.05 $0.05
23 Jul 2021 $0.05 $0.00 0.00% 472,688 $0.05 $0.05 $0.05
22 Jul 2021 $0.05 $0.00 0.00% 777,342 $0.05 $0.05 $0.05
21 Jul 2021 $0.05 $0.00 0.00% 192,309 $0.05 $0.05 $0.05
20 Jul 2021 $0.05 $0.00 0.00% 508,517 $0.05 $0.05 $0.05
19 Jul 2021 $0.05 $0.00 0.00% 204,975 $0.05 $0.05 $0.05
16 Jul 2021 $0.05 $0.00 0.00% 2,922,048 $0.05 $0.05 $0.05
15 Jul 2021 $0.05 $0.00 0.00% 842,162 $0.05 $0.05 $0.05
14 Jul 2021 $0.05 $0.00 0.00% 1,012,013 $0.05 $0.05 $0.05
13 Jul 2021 $0.05 $0.00 0.00% 611,361 $0.05 $0.05 $0.05
12 Jul 2021 $0.05 $0.00 0.00% 3,347,658 $0.05 $0.05 $0.05
09 Jul 2021 $0.05 $0.00 0.00% 594,123 $0.05 $0.05 $0.05
08 Jul 2021 $0.05 $0.00 0.00% 237,539 $0.05 $0.05 $0.05
07 Jul 2021 $0.05 $0.00 0.00% 670,420 $0.05 $0.05 $0.05
06 Jul 2021 $0.05 $0.00 0.00% 1,435,668 $0.05 $0.05 $0.05

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
05 Oct 2020 Lisa Gray Sell 8 $607,281
Off-market trade.
11 Aug 2020 Richard Hopkins Issued 1 $50,000
Placement.
11 Aug 2020 Oludare Odumosu Issued 25 $1,300,000
Issue of securities.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Harry Karelis Executive DirectorExecutive Deputy Chairman Nov 2016
Mr Karelis is the Chairman of Gemelli Group and has more than 28 years of experience in the financial services sector including fundamental analysis, funds management and private equity investing and has been involved in numerous cross border activities across a number countries.
Mr Jason William Peterson Non-Executive Director Nov 2016
Mr Peterson is Managing Director of CPS Capital and has more than 25 years of experience in the finance sector, which he obtained by working in both local and international stockbroking companies. He has experience in corporate structuring, capital raisings, corporate and strategic advice to small and medium size companies in addition to reverse takeovers.
Dr Oludare Odumosu Managing Director Dec 2019
Dr Odumosu has over 10 years in corporate pharmaceutical business development, strategy & operational leadership including alliance management. Dr Odumosu has experiences from several academic, public health and life science organisations. In his recent role as Ilera Healthcare's Chief Operating Officer, Dr Odumosu led the design, implementation and management of Ilera's business operations in 2018. He was also responsible for management of day to day operation of Ilera's vertically integrated grow/processor, wholesale and dispensary. He led the formulation of Ilera proprietary cannabinoid-based product.
Mr Osagie Imasogie Non-Executive ChairmanNon-Executive Director Dec 2019
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital. Prior to co-founding PIPV Capital, Osagie established GlaxoSmithKline Ventures and was its founding Vice President. Mr Imasogie has held senior legal, commercial and R&D positions within pharmaceutical companies such as GSK, SmithKline, DuPont Merck and Endo, where he was the founding General Counsel and SVP for Corporate Development. Osagie has also been a Price Waterhouse Corporate Finance Partner as well as a practicing attorney with US Law Firm.
Ms Lisa Gray Non-Executive Director Dec 2019
Ms Gray has experience in finance, marketing, business development, and operations primarily within the pharmaceutical industry. Lisa was Co-Founder and Vice Chair of Ilera Healthcare. Lisa is also the Co-Founder and Managing Partner of PIPV Capital where she manages the financial aspects of the firm and portfolio, generates and leads investments, manages investor communications, and acts as Board Member CEO, CFO, and/or has various management roles, as necessary, for portfolio companies. Lisa has previously served as COO for GlaxoSmithKline (GSK) Pharmaceuticals Ventures as well as other operations and transactions roles over 13 years with GSK. Prior to joining GSK, Lisa was a management consultant and auditor with Coopers & Lybrand.
Mr Timothy (Tim) Ryan Slate Company Secretary Dec 2016
-
Timothy (Tim) Ryan Slate Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Sunset Capital Management Pty Ltd 55,413,617 4.85%
Gemelli Nominees Pty Ltd 49,587,680 4.34%
Mara Gordon 44,142,326 3.86%
Mal Washer Nominees Pty Ltd 35,198,688 3.08%
Capricorn Investment Partners (Nominees) Pty Ltd 17,577,883 1.54%
Citicorp Nominees Pty Limited 16,756,434 1.47%
HSBC Custody Nominees (Australia) Limited 16,699,968 1.46%
Mr Torsten M Geers 16,413,065 1.44%
Mr Zoltan Kerekes 16,413,065 1.44%
Ms Lisa Gray 16,413,065 1.44%
Osagie Imasogie 16,413,065 1.44%
Sharri J Rochlin 16,413,065 1.44%
Ubs Nominees Pty Ltd 15,800,000 1.38%
JP Morgan Nominees Australia Pty Limited 13,930,688 1.22%
Mera I LLC \C 13,879,566 1.22%
Mr Amit Gupta 11,529,999 1.01%
Celtic Capital Pty Ltd 11,200,000 0.98%
Copper Lake Holdings Limited 10,075,203 0.88%
Mr Alan Trounson 10,075,203 0.88%
Xena Advisors Llc 8,888,889 0.78%

Profile

since

Note